CAHAN - Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from RSV during the 2023–2024 Respiratory Virus Season

The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to provide options for clinicians to protect infants from respiratory syncytial virus (RSV) in the context of a limited supply of nirsevimab, a long-acting monoclonal antibody immunization product recommended for preventing RSV-associated lower respiratory tract disease in infants.

Please see the full CDC Health Advisory here: https://emergency.cdc.gov/han/2023/han00499.asp